Introduction
AI is not what will transform regulatory affairs in life sciences. A new operating model will, and AI is just one of its tools.
Over the past few years, almost every regulatory function has launched an AI pilot. Teams are testing generative AI to draft clinical summaries, automate labelling updates, extract data for submissions and monitor regulatory intelligence. Many of these pilots show impressive time savings in isolation.
Yet few organisations have seen those gains carry through to faster approvals, lower compliance risk or a leaner regulatory cost base. The reason is simple: the tools have changed, but the operating model underneath them has not. Work is still organised around documents, handoffs and country-by-country processes designed decades ago.
This article looks at why AI adoption alone is not enough, and what a reimagined regulatory operating model looks like across data, process, people, governance and partnerships.
Why AI Adoption Alone Falls Short
Most regulatory AI programmes automate tasks inside an old process instead of redesigning the process. Five patterns explain why the value stalls.
1. AI bolted onto document-centric work. Regulatory information still lives in Word files, PDFs and spreadsheets. AI can draft a document faster, but someone still has to review, reconcile, format and re-author it for every market.
2. Fragmented data. Product, labelling, CMC, clinical and safety data sit in separate systems owned by separate teams. AI models are only as reliable as the data they draw on, and inconsistent master data produces inconsistent outputs.
3. Pilots without a path to scale. Use cases are chosen by enthusiasm rather than value. Each is validated, funded and governed on its own, so successes rarely move into everyday operations.
4. Unchanged roles and incentives. If reviewers are still measured on documents produced and checked, saved time is absorbed by more checking. People need new roles, skills and confidence to trust AI-assisted work.
5. Governance that lags behind. Without clear rules on validation, human oversight and accountability, quality and compliance teams default to caution. That caution, while understandable, slows every deployment.
The regulatory landscape is shifting too
Regulators are not standing still, and the operating model has to keep pace with them, not just with technology.
- Clearer expectations for AI in submissions. In January 2025, the FDA published draft guidance proposing a risk-based credibility framework for AI models that support regulatory decisions on drugs and biologics. It asks sponsors to define each model’s context of use and show evidence proportionate to its risk (FDA draft guidance overview).
- Transatlantic alignment. On 14 January 2026, the EMA and FDA jointly published Guiding Principles of Good AI Practice in Drug Development. They apply across the full medicines lifecycle and stress a risk-based approach, clear context of use, robust data governance and lifecycle management (Jones Day).
- Horizontal AI regulation. The EU AI Act has been in force since August 2024. It adds risk classification, documentation and oversight duties that regulatory teams increasingly need to interpret (IntuitionLabs).
- Structured data over documents. Initiatives such as IDMP, electronic product information and structured quality submissions are moving regulators towards data that can be exchanged and reused, not just read.
- Regulators using AI themselves. Agencies are deploying AI to support their own reviews. Sponsors that submit clean, consistent, well-structured data will benefit most from faster, more automated assessment.
The direction is clear: regulators expect sponsors to govern AI responsibly and to manage regulatory information as structured, traceable data. Both demand operating model change, not just new tools.
Five pillars of a reimagined regulatory operating model
A future-ready regulatory function rests on five connected pillars. AI strengthens each one, but none of them depends on AI alone.
1. Data as the Foundation
The shift starts by treating regulatory content as structured data, not documents. Product, registration, labelling and CMC information is held once, governed centrally and reused across submissions and markets.
- A single, trusted source of regulatory master data, aligned with IDMP standards
- Structured content authoring with reusable, pre-approved content blocks
- End-to-end traceability from source data to submitted claim
With this foundation in place, AI can generate, check and compare content reliably, because it draws on consistent, governed data.
2. Processes Redesigned End to End
Instead of speeding up each step, the reimagined model asks which steps should exist at all. Processes are designed around outcomes, such as approval or a compliant label change, rather than departmental handoffs.
- Fewer manual handoffs between regulatory, clinical, CMC, safety and commercial teams
- Global-first submission planning, with local variation managed by exception
- Continuous compliance monitoring instead of periodic, manual checks
- Humans in the loop at defined decision points, not at every step
3. People and New Roles
Technology changes tasks; people change outcomes. Regulatory professionals move from authoring and checking documents to strategy, judgement and oversight.
- New roles such as regulatory data stewards, AI product owners and regulatory technologists
- Upskilling in data literacy, prompt design and AI output review
- Performance measures based on outcomes, not documents produced
- Change management that builds trust in AI-assisted work
4. Governance Built for AI
Governance should enable responsible speed, not block progress. A clear framework gives quality, compliance and regulatory teams the confidence to scale.
- A risk-based classification of AI use cases, aligned with FDA and EMA expectations
- Defined validation, monitoring and change-control processes for AI models
- Clear accountability: who owns each model, its outputs and its decisions
- Audit trails that show how every AI-assisted output was produced and reviewed
5. An Ecosystem of Partners
No organisation builds everything itself. The reimagined model decides deliberately what to keep in-house, what to share and what to source.
- Strategic capabilities, such as regulatory strategy and agency interactions, kept close
- Scalable operations, such as publishing, labelling and lifecycle maintenance, delivered through partners and platforms
- Interoperable technology that connects RIM, quality, safety and clinical systems
- Active participation in industry standards and regulator engagement
What changes in practice
The difference between AI adoption and operating model change shows up in everyday work.
| Area | AI Adoption Only | Reimagined Operating Model |
|---|---|---|
| Regulatory content | AI drafts documents faster | Content is structured data, reused across submissions and markets |
| Submissions | Each market prepared separately | Global-first planning, local variation by exception |
| Labelling | AI helps compare label versions | Label changes flow automatically from a single source of truth |
| Regulatory intelligence | AI summarises new guidance | Changes are linked to affected products and trigger impact assessments |
| Quality review | Every output checked manually | Risk-based review at defined decision points |
| Roles | Same roles, new tools | New roles in data stewardship, AI oversight and regulatory technology |
| Governance | Each pilot approved one by one | A standing AI governance framework with clear risk tiers |
| Measurement | Hours saved per task | Time to approval, right-first-time rate, compliance risk |
A Practical Roadmap
Operating model change is a journey, not a single project. A phased approach builds value early while laying the right foundations.
Assess and align. Map current regulatory processes, data flows, systems and pain points. Agree on a target operating model and the business outcomes it must deliver, such as faster approvals or lower lifecycle maintenance cost.
Build the foundations. Clean and connect regulatory master data, set up structured content and put an AI governance framework in place. These steps unlock every later use case.
Redesign priority processes. Choose two or three high-value processes, such as label change management or post-approval CMC variations. Redesign them end to end, with AI embedded from the start.
Scale and industrialise. Extend proven models across products, markets and functions. Move successful use cases from pilots into validated, monitored production.
Continuously improve. Track outcomes, monitor AI performance and evolve the model as regulators, technology and the portfolio change.
The most important principle is to start with the problem, not the technology. Every initiative should trace back to a measurable regulatory or business outcome.
Measuring success beyond efficiency
Hours saved is the easiest metric to report and the least meaningful. A reimagined operating model should be judged by what it delivers for patients, regulators and the business.
| Dimension | What to Measure |
|---|---|
| Speed | Time from data lock to submission; time to approval; time to implement label changes |
| Quality | Right-first-time submission rate; number of agency questions; deficiency letters |
| Compliance | Open compliance gaps; overdue commitments; audit and inspection findings |
| Cost | Cost per submission; lifecycle maintenance cost per product |
| Scale | Share of processes running on structured data; AI use cases in validated production |
| People | Time spent on strategic versus administrative work; skills coverage; employee confidence in AI |
Tracking these measures keeps the programme focused on outcomes and makes the case for continued investment.
Conclusion
AI will not transform regulatory affairs on its own. The organisations that pull ahead will be those that rethink how regulatory work is structured: data treated as a strategic asset, processes redesigned end to end, people equipped for new roles, governance built for responsible speed, and partners chosen deliberately.
The question for regulatory leaders is no longer whether to adopt AI. It is whether their operating model is ready to turn AI into faster approvals, stronger compliance and better outcomes for patients.
At Pharma Wizard Consultancy, we help life sciences organisations make that shift. We combine regulatory expertise, data and technology capabilities, and practical change management to design and deliver operating models built for what comes next. Contact Pharma Wizard Consultancy to start the conversation about your regulatory future.




